Intismeran Autogene Therapy: An End-to-End Pathway From Tumor Tissue to Individualized Neoantigen Treatment for Patients With Cancer
JCO Oncology Advances · 2026-07 · 3 (3)
DOI: 10.1200/oa-25-00206 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Oncology Advances, 2026-07. Verfasst von Laureen S. Ojalvo und 6 weiteren Autor:innen. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 10 Literaturangaben.
Abstract (Originalsprache)
Intismeran autogene (V940/mRNA-4157; hereafter referred to as intismeran) is an individualized mRNA-based cancer immunotherapy targeting tumor-specific neoantigens. As a first-in-class therapy, intismeran is under clinical investigation across a range of settings, from early-stage disease (neoadjuvant and adjuvant) to advanced metastatic cancers—a broad clinical development program bolstered by positive phase II data in high-risk, resected melanoma. This article describes the process by which intismeran doses are generated and delivered to clinical sites, with an emphasis on individualized operational and manufacturing processes. Experience in intismeran early-phase trials provides confidence in the transition to broader, real-world oncologic applications.
Zitieren
APA
Ojalvo, L. S., Posadas, T., Chattopadhyay, N., Porichis, F., Shah, S., Cristescu, R., & Rao, A. (2026). Intismeran Autogene Therapy: An End-to-End Pathway From Tumor Tissue to Individualized Neoantigen Treatment for Patients With Cancer. JCO Oncology Advances, 3(3). https://doi.org/10.1200/oa-25-00206
Vancouver
Ojalvo LS, Posadas T, Chattopadhyay N, Porichis F, Shah S, Cristescu R, et al. Intismeran Autogene Therapy: An End-to-End Pathway From Tumor Tissue to Individualized Neoantigen Treatment for Patients With Cancer. JCO Oncology Advances. 2026;3(3). doi:10.1200/oa-25-00206
BibTeX
@article{Ojalvo2026,
author = {Ojalvo, Laureen S. and Posadas, Tracey and Chattopadhyay, Nibedita and Porichis, Filippos and Shah, Sukrut and Cristescu, Razvan and Rao, Anjali},
title = {Intismeran Autogene Therapy: An End-to-End Pathway From Tumor Tissue to Individualized Neoantigen Treatment for Patients With Cancer},
journal = {JCO Oncology Advances},
year = {2026},
volume = {3},
number = {3},
doi = {10.1200/oa-25-00206}
}
EUVIMED